ZYBERNO
Stock Report
Updated Aug 31, 2026

BIOHARVEST SCIENCES INC. (BHST)

Healthcare • NASDAQ

$1.91

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
BIOHARVEST SCIENCES INC. (BHST) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):GOOD (0.43x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-78.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIOHARVEST SCIENCES INC. (BHST) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.91
Market Cap:$43.29M

Valuation Multiples (3)

P/B Ratio:1.70x
P/S Ratio:1.25x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$23.19M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-17.5%
Fundamental Growth Rate (g):13.7%

Margin Analysis (1)

Ebitda Margin:-11.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.97x
Quick Ratio:3.38x
Cash Ratio:3.00x

Leverage Analysis (3)

Debt To Equity Ttm:0.43x
Debt-to-Equity Ratio:0.43x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:22,816,000.00
Cash And Cash Equivalents:23,025,000.00
Long Term Debt:$1.98M
Net Debt:-$20.11M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$34.51M
Cost Of Revenue Ttm:$14.03M

Profitability Breakdown (2)

$20.48M-$5.58M

Bottom Line Performance (3)

-$11.14M
Income Before Tax:-$11.06M
Ebitda Ttm:-3,951,000.00

Operating Expenses (5)

Operating Expenses:26,051,000.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$76.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-11.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$47.67M
Current Assets:$30.50M
Ppe Net:8,326,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:22,217,000.00
Current Liabilities:7,684,000.00
Long Term Debt:$1.98M
Short Term Debt:$935.00K

Equity & Capital (3)

Equity:$25.45M
Retained Earnings:-$107.55M
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:1,981,000.00
Inventory:4,559,000.00
Accounts Payable:2,627,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:601,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$7.23M-$9.58M

Investment Activities (1)

Investing Cash Flow:-$2.37M

Financing Activities (3)

Financing Cash Flow:$30.19M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:18,262,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.49

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.52
Operating Cash Flow Per Share:-$0.32

Book Value & Capital (2)

Book Value Per Share:$1.12
Cash Per Share:1.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.72x
Working Capital Turnover Ttm:1.51x

Receivables Management (2)

Receivables Turnover Ttm:17.42x
Days Sales Outstanding Ttm:20.95

Inventory Management (2)

Inventory Turnover Ttm:3.08x
Days Inventory Outstanding Ttm:118.59

Payables & Cash Cycle (2)

Days Payable Outstanding:68.33
Cash Conversion Cycle:71.21
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-17.5%
Fundamental Growth Rate (g):13.7%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BHST
Company Name:BIOHARVEST SCIENCES INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Canada

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:22.67M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 22:59:02 UTC
Data Timestamp:2026-08-20T02:32:48.408985
Scroll to Top